Posted by Michael Wonder on 05 Aug 2020
Cerecor receives rare paediatric disease designation for CERC-006 in lymphatic malformations
4 August 2020 - Cerecor today announced that the U.S. FDA granted rare paediatric disease designation to CERC-006, a dual inhibitor of mTOR complexes 1 and 2 for the treatment of lymphatic malformations.
CERC-006 is an orally available blocker of mTOR complex 1 and 2 that is being developed for the treatment of serious lymphatic malformations not treatable with surgery or sclerotherapy.
